RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Huashan Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorHuashan Hospital复旦大学附属华山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06054906, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Current participation in an interventional clinical study or treatment with another investigational drug or use of an investigational device within 4 weeks prior to the first dose of study drug

    Exclusion criterion 2

    Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or agents targeting CTLA-4, OX-40, CD137, etc.

    Exclusion criterion 3

    Diagnosis of a malignant disease other than gastric cancer within 5 years prior to the first dose of therapy

    Exclusion criterion 4

    Active autoimmune disease requiring systemic therapy within 2 years prior to the first dose of the drug

    Exclusion criterion 5

    Have received systemic systemic therapy with proprietary Chinese medicines with antitumor indications or immunomodulatory drugs within 2 weeks prior to the first administration of the drug

    Exclusion criterion 7

    Have received systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of treatment

    Exclusion criterion 8

  3. ECOG PS: 0-1 score

    Inclusion criterion 6

  4. Known history of HIV infection

    Exclusion criterion 12

    Active HCV infection

    Exclusion criterion 14

  5. Negative pregnancy test in women of childbearing age

    Inclusion criterion 9

    Need to use contraception with an annual failure rate of less than 1% if there is a risk of conception

    Inclusion criterion 10

    Pregnant or lactating women

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06054906, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Signed written Informed Consent Form
  • Male or female, age ≥ 18 years old
  • Histologically confirmed gastric adenocarcinoma, diagnosed as locally progressive according to the AJCC 8th ed, cTNM diagnosis of cT3-4aN1-3M0 and resectable lesion as assessed by the investigator
  • No prior systemic therapy such as surgery, radiotherapy, or immunotherapy for the disease at hand
  • Consent to radical surgical treatment and no contraindications to surgery as determined by the surgeon
  • ECOG PS: 0-1 score
  • Expected survival > 6 months
  • Adequate organ function, must meet the following laboratory specifications:

8.1 Absolute neutrophil count (ANC) ≥ 1.0x10\^9/L; 8.2 Platelets ≥ 80x10\^9/L; 8.3 Hemoglobin > 7g/dL; 8.4 Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (Total bilirubin > 1.5 x ULN but direct bilirubin ≤ ULN are allowed to be enrolled); 8.5 AST, ALT ≤ 2.5×ULN; 8.6 Blood creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 60 ml/min; 8.7 INR or PT ≤ 1.5 times ULN; 8.8 TSH within normal range (Enrollment allowed if baseline TSH is outside normal range but FT4 is within normal range); 8.9 Myocardial enzyme profile within normal range;

  • Negative pregnancy test in women of childbearing age
  • Need to use contraception with an annual failure rate of less than 1% if there is a risk of conception

Exclusion Criteria:

  • Endoscopically show signs of active bleeding from the lesion
  • Current participation in an interventional clinical study or treatment with another investigational drug or use of an investigational device within 4 weeks prior to the first dose of study drug
  • Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or agents targeting CTLA-4, OX-40, CD137, etc.
  • Diagnosis of a malignant disease other than gastric cancer within 5 years prior to the first dose of therapy
  • Active autoimmune disease requiring systemic therapy within 2 years prior to the first dose of the drug
  • Live vaccination within 30 days prior to the first administration of the drug
  • Have received systemic systemic therapy with proprietary Chinese medicines with antitumor indications or immunomodulatory drugs within 2 weeks prior to the first administration of the drug
  • Have received systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of treatment
  • Has not fully recovered from any intervention-induced toxicity and/or complications (excluding malaise or alopecia) prior to initiation of therapy
  • Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation
  • Known hypersensitivity to drugs used in this study
  • Known history of HIV infection
  • Untreated active hepatitis B
  • Active HCV infection
  • Pregnant or lactating women
  • The presence of any serious or uncontrolled systemic disease
  • Other factors that, in the judgment of the investigator, may affect the outcome of the study

Quoted from ClinicalTrials.gov, NCT06054906, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06054906, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06054906